Polarean Imaging Valuation
Is POLX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of POLX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate POLX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate POLX's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for POLX?
Key metric: As POLX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is POLX's PS Ratio? | |
|---|---|
| PS Ratio | 12.5x |
| Sales | US$1.87m |
| Market Cap | US$23.41m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.5x |
| Enterprise Value/EBITDA | -1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does POLX's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 10.8x | ||
OBI Ondine Biomedical | 24.5x | 66.0% | UK£22.5m |
IHC Inspiration Healthcare Group | 0.4x | 13.6% | UK£14.6m |
EMVC EMV Capital | 6.2x | 49.2% | UK£11.3m |
BELL Belluscura | 12x | 151.8% | UK£16.0m |
POLX Polarean Imaging | 12.5x | 57.3% | UK£18.7m |
Price-To-Sales vs Peers: POLX is expensive based on its Price-To-Sales Ratio (12.5x) compared to the peer average (10.8x).
Price to Sales Ratio vs Industry
How does POLX's PS Ratio compare vs other companies in the GB Medical Equipment Industry?
| 4 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
SPEC INSPECS Group | 0.3x | 5.5% | US$68.70m |
YGEN Yourgene Health | 0.6x | n/a | US$20.48m |
IHC Inspiration Healthcare Group | 0.4x | 13.6% | US$18.23m |
SUN Surgical Innovations Group | 0.4x | n/a | US$6.42m |
| 4 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: POLX is expensive based on its Price-To-Sales Ratio (12.5x) compared to the UK Medical Equipment industry average (3x).
Price to Sales Ratio vs Fair Ratio
What is POLX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 12.5x |
| Fair PS Ratio | 5.4x |
Price-To-Sales vs Fair Ratio: POLX is expensive based on its Price-To-Sales Ratio (12.5x) compared to the estimated Fair Price-To-Sales Ratio (5.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Guerbet
€331.6m
Engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.
0ELV
€26.50
7D
-8.0%
1Y
42.5%
LNA Santé
€242.3m
Engages in the management and operation of health establishments.
0OR2
€23.70
7D
-6.7%
1Y
17.3%
Arjo
SEK 8.9b
Develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia and Pacific, South America, Africa, and internationally.
0HQ8
SEK 32.93
7D
-4.0%
1Y
-11.1%